Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2011; 17(11): 1494-1500
Published online Mar 21, 2011. doi: 10.3748/wjg.v17.i11.1494
Table 1 Baseline characteristics-127 patients treated with Histoacryl® -injection therapy
Clinical characteristics of patientsNumber%
No. of patients (male/female)127(97/30)76.4/23.6
Mean age (yr)55.69
Etiology of gastric varices
Liver cirrhosis127100
Hepatitis B5039.3
Hepatitis C107.9
Alcoholic4837.8
Unknown1915
Association of hepatocellular carcinoma2116.5
Child-pugh classification (A/B/C)42/59/2633.1/46.4/20.5
Bleeding status
< 24 h4837.8
> 24 h5241
Prevention2721.2
Sarin classification of gastro-esophageal varices
GOV15644.1
GOV26148
IGV186.3
IGV221.6
Form of gastric varices
F11512
F25644.4
F35543.6
Table 2 Baseline Characteristics-27 patients who underwent primary prophylaxis
Clinical characteristicsNumber%
No. of patients (male/female)27(21/6)71.4/28.6
Mean age (yr)55.29
Etiology of gastric varices
Liver cirrhosis27100
Hepatitis B1451.9
Hepatitis C311.1
Alcoholic622.2
Unknown414.8
Association of hepatocellular carcinoma518.5
Child-Pugh classification (A/B/C)12/11/444.4/40.7/14.9
Sarin classification of gastro-esophageal varices
GOV11555.6
GOV21037
IGV127.4
IGV200
Form of gastric varices
F1311.1
F2933.3
F31555.6
Table 3 Results of 127 Histoacryl®-injection patients
Result of Histoacryl® injectionNumber%
No. of sessions
19877.1
22519.7
3-5 (3/5)4 (3/1)3.2
Mean number of sessions1.3 ± 0.6
Mean injection volume (cc)1.7 ± 1.3
Initial hemostasis12598.4
Number of rebleeding2922.8
Duration of rebleeding
< 5 d43.1
< 6 wk107.9
< 1 yr97.1
Successful hemostasis of rebleeding2273.9
Table 4 Results of 27 patients with primary prophylaxis
Result of Histoacryl® injectionNumber%
No. of sessions
12177.8
2414.8
3-5 (3/5)2 (1/1)3.7/3.7
Mean number of sessions1.37
Mean injection volume (cc)2.1
Number of patients27
Death414.8
Hepatic failure311.1
Hepatocellular carcinoma13.7
Prophylactic treatment- related complication00
Table 5 Complications of Histoacryl® injection
ComplicationsNumber
Pulmonary embolism1
Adrenal abscess2
Splenic infarction1
Bacteremia2
Fever44
Abdominal pain22
Table 6 Predictive factors of rebleeding within 1 year
Clinical characteristicsRebleedingNon rebleedingP
Sex0.597
Male1780
Female624
Etiology0.707
Hepatitis B1139
Hepatitis C28
Alcoholic66
Unknown44
Association of hepatocellular carcinoma0.000
Yes912
No1492
Sarin classification of gastro-esophageal varices0.009
GOV1848
GOV21546
Form of gastric varices0.269
F1114
F21145
F31144
Duration0.815
< 24 h1780
> 24 h624
CTP grade0.230
A636
B952
C816